{"entity":{"id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","aka":[],"tldr":"A phase 1/2 trial of YH32367 in advanced solid tumours, run by Yuhan Corporation, now recruiting.","summary":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor is a phase 1/2 interventional study registered as NCT05523947 by Yuhan Corporation, with 147 participants planned, started 2022-08-26 and due to reach its primary completion in 2028-03-31. Interventions recorded: YH32367.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05523947","url":"https://clinicaltrials.gov/study/NCT05523947"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05523947","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors","sponsor":"Yuhan Corporation","enrolled":147,"outcomes":[]},"route":"/trials/nct05523947/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}